Nuwellis, Inc. (NASDAQ:NUWE) Q4 2022 Earnings Call Transcript

Nuwellis, Inc. (NASDAQ:NUWE) Q4 2022 Earnings Call Transcript February 28, 2023

Operator: Good morning, and welcome to the Nuwellis Fourth Quarter and Full Year 2022 Earnings Conference Call. Please note that this event is being recorded. Now I’d like to turn the call over to Ms. Vivian Cervantes, Investor Relations. Please go ahead.

Vivian Cervantes: Thank you, operator. Hi, everyone. Thank you for joining us in today’s conference call to discuss Nuwellis’ corporate developments and financial results for the fourth quarter and full year ended December 31, 2022. In addition to myself, with us today are Nestor Jaramillo, Nuwellis’ President and CEO; and Lynn Blake, CFO. At 8:00 a.m. Eastern today, Nuwellis released financial results for the quarter and year ended December 31, 2022. If you have not received Nuwellis’ earnings release, please visit the Investors page on the company’s website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today’s call will be protected under the Private Securities Litigation Reform Act of 1995.

Any statements that relate to expectations or predictions of future events and market trends as well as our estimated results or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties and could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company’s filings with the SEC including the latest 10-K and subsequent reports.

With that, I now would like to turn the call over to Nestor.

Nestor Jaramillo: Thank you, Vivian, and good morning, everyone. Welcome to Nuwellis fourth quarter 2022 earnings conference call. On today’s call, I will provide an overview of our fourth quarter and full year performance, and give an update on our strategic initiatives. Our Chief Financial Officer, Lynn Blake, will then provide detailed financial results before opening the call for questions, followed by my closing remarks. 2022 proved to be a year of growth for Nuwellis with 42% year-over-year revenue growth in the fourth quarter, a revenue increase of 13% sequential and an 8% revenue growth for the full year. Revenue growth in the quarter was led by our Pediatric segment, which increased 92% year-over-year. This was followed by 47% growth in our Heart Failure segment and 24% growth in our Critical Care segment.

Our momentum continues to be fueled by the execution of two key growth strategies that we have mentioned in the past. First, our expansion in the field organization, especially with our clinical education specialists, or CESs. Our CESs played an important role supporting our account managers within the inpatient and outpatient facility, and I will provide more detail later in the call. The second initiative that fueled our momentum in Q4 is the growing body of clinical evidence in the last 7 months supporting the use of the Aquadex in all the three segments of our business. I’d now like to turn to the business update on our key strategic initiatives, starting with growing our clinical body of evidence. A key area for us, an investment at Nuwellis, is having a robust clinical evidence.

In doing so, we have more leverage to change practice guidelines towards making Aquadex the standard of care for fluid overload and further driving clinical adoption. We are pleased to be able to announce many new publications, poster presentations at medical conferences and peer reviewed data further reinforcing Nuwellis technology in cardiac surgery, heart failure and pediatrics throughout 2022 and thus far in 2023. As previously mentioned, cardiac surgery, we have two peer review publications. On August 31, we announced the publication of a new peer reviewed clinical data demonstrating 100% survival at 30 days following the use of ultrafiltration in high-risk post-operative coronary artery bypass grafting, or cabbage, patients. In January of this year, the annals of thoracic surgery, the authors commented on a key term order set or hospital protocol for cardiac surgery associated acute kidney injury that included a recommendation to use ultrafiltration for post-cardiac surgery patients that are unresponsive to diuretics.

This recommendation validate our Aquadex therapy to improve outcomes post-cardiac surgery and is supportive of our goal to leverage our body of clinical evidence to change practice guidelines for ultrafiltration. In the Heart Failure segment, we highlighted the multicenter controlled randomized clinical trial called AVOID-HF that was analyzed under the newly favored statistical analysis called Win Ratios. This new analysis presented at the 2022 Heart Failure Society of America Scientific Meeting showed the strong benefit of ultrafiltration over diuretics in reducing cardiovascular mortality and heart failure events at 30 and 90 days, included overload heart failure patients who are unresponsive to diuretics. In addition, in the fourth quarter, we announced a peer reviewed publication of a single center 10-year real-world retrospective study of 355 consecutive patients supporting lower heart failure hospitalization and readmissions in a year after using the Aquadex.

The data demonstrated 81% lower heart failure hospitalizations per year and a 48% decrease in rehospitalizations from the national average of 30 days. We are now actively leveraging this data to educate providers and facilities of the economic benefit and cost savings Nuwellis can provide with the use of the Aquadex system in both inpatient and outpatient setting, as well as the improved quality of life in patients. We also continue to make progress on our pivotal REVERSE-HF trial. As a reminder, the primary effectiveness end point of REVERSE-HF will evaluate mortality and heart failure events within 30 and 90 days as the comparison between Aquadex therapy and intravenous loop diuretics. To date, we have activated nine clinical study sites and we are on track to achieve our Q1 2023 milestone of 12 sites enrolled by the end of the first quarter.

We expect to present the results of this study to the medical societies responsible for establishing medical guidelines. Further, in Pediatrics, the fastest-growing segment of our business, we announced peer-reviewed data demonstrating 71% survival in kidney replacement therapy used in Aquadex in low birthweight preterm neonates. Finally, completing our clinical program, I would like to extend my warm welcome to Dr. John Jeffries, our new Chief Medical Officer. Dr. Jeffries brings with him over two decades of cardiology and heart failure expertise, both adult and pediatric patients. And we are excited to have him in our team as we continue to build our clinical body of evidence. Our second strategic initiatives involve the targeted expansion of our commercial footprint to drive penetration.

This includes both expansion of our commercial team and our installed base of active accounts. As of the end of Q4, we are pleased to be able to say that we have now filled all open sales leadership, account management and clinical education positions. As previously noted, our clinical education specialists, or CES, all of whom are trained nurses, directly partner with the patient care team on the optimal use of our ultrafiltration system. In so doing, they facilitate not only successful patient outcomes, but also support increased use of our therapy across multiple specialty units in the hospital in addition to helping drive adoption at new targeted facilities. As for our expansion of our installed base, console placements, the razor in our razor blade model, increased more than 6x in the fourth quarter compared to the year ago period and increased 44% in 2022 versus prior year with focused expansion in key geographic locations and high-volume centers.

We achieved record U.S. console sales in Q4 with 20 consoles sold. To date, we have established a strong foot in the East Coast and in the U.S. Turning now to our third strategic initiative of targeting outpatient clinics treating heart failure patients. Through our research, we have found many real-world case studies that suggest the current standard of care, managing fluid overload, heart failure patients is extremely costly for both patients and hospitals due to higher cost of care and high hospital readmission rates. According to the data, it cost over $24,000 per patient per encounter to treat a heart failure patient hospitalized for average of 8 days, in addition to the unreimbursed cost of hospital readmissions within 30 days. As mentioned before, we now have the clinical evidence demonstrating that Aquadex reduces heart failure hospitalization by 81% and lower heart failure readmission rates by over 50%, thereby decreasing both the total cost of care and unreimbursed cost of the hospitalization.

Another major milestone of Nuwellis in ’22 was the assignment by the American Medical Association of a new dedicated Category 3 CPT code for therapeutic ultrafiltration. We have been leveraging this code in our conversations to reactivate outpatient clinics who had previously been using Aquadex but later discontinued use due to the lack of reimbursement. We continue to believe that there is a line of sight toward our goal of achieving a Category 1 CPT code in two to three years, which will allow Nuwellis to further leverage the benefit of Aquadex for providers and facilities alike. Turning now to our fourth strategic initiative, which is on the product development front as well as the strategic partnerships. I will begin with an update on our recent announced exclusive U.S. licensing and distribution agreement for SeaStar Medical’s Selective Cytopheretic Device, or SCD, for preventive pediatric acute kidney injury.

Clinical studies have demonstrated that SCD’s potential to eliminate dialysis dependency shorten ICU time and restore the lives of critical EO pediatric patients. This agreement further reinforces our previously communicated decision to focus on the pediatric segment and also further expand our product portfolio and enabling us to save more lives in this underserved patient population. SeaStar Medical expects the FDA to complete its review of a Humanitarian Device Extension, or HDE, for the use of its SCD in children in the first half of this year. We look forward to keeping you updated on the progress in the coming weeks and months. On the product development front, we are on track with progress on our pediatric continuous renal replacement therapy device and continue to anticipate IDE submission by early 2024.

Early feedback from physicians, and pediatric nephrologists in particular, have been enthusiastic, noting how our technology uniquely addresses the unmet need of this patient population and could potentially be a game changer in pediatric treatment. In conclusion, I want to reiterate how excited I am for the future of Nuwellis. Our goal of making Aquadex therapy, the standard of care for restoring fluid balance remains intact. We believe we are approaching an inflection point towards reaching this goal. The work that we did in 2022 advanced us down this path, and I look forward to continue a strong execution in 2023 and beyond. Now I would like to turn the call over to our Chief Financial Officer, Lynn Blake, to discuss our Q4 and full year 2022 results.

Lynn Blake: Thank you, Nestor, and good morning, everyone. Since joining Nuwellis last October, I continue to be increasingly excited about this company’s future. Our Q4 revenue growth of 42% is attributed to the success of our commercial team expansion, advancements in our clinical evidence development and our tenacity in increasing market awareness of treatment options for patients with fluid overload. Turning to the Q4 financial results. Revenue for the fourth quarter was $2.3 million, representing 42% year-over-year growth and a 14% sequential increase from the third quarter of 2022. Our Pediatric Products segment once again had the strongest growth in the quarter with a 92% increase year-over-year. This was followed by 47% growth in our Heart Failure segment and 24% growth in Critical Care.

Gross margin for the quarter was 56.9% of sales, an increase of 250 basis points compared to gross margin of 54.4% in the prior year. This increase was primarily driven by increased sales volume in the quarter. Selling, general and administrative expenses were $4.7 million in the fourth quarter. Compared to the fourth quarter of 2021, SG&A expenses increased by approximately $570,000 or 14%. Compared to the third quarter of 2022, SG&A expenses increased by approximately $413,000 or 10%, reflecting increased variable compensation expenses and professional fees in the fourth quarter. Fourth quarter research and development expense was $1.2 million, an increase of $70,000 or 6% relative to the fourth quarter of 2021. On a sequential quarter basis, research and development costs increased $273,000 or 29%, all related to the planned development of our new pediatric dedicated device.

Total operating expenses were $5.9 million in the quarter, an increase of approximately $640,000 compared to the fourth quarter of 2021. Total operating expenses for the full year were $21.9 million, a decrease of approximately $2.1 million or 9% year-over-year we focused on conserving cash, while at the same time funding our top strategic incentives. Our 2022 full year cash utilization decreased 15% year-over-year, reflecting continued expense vigilance. The net loss in the fourth quarter was $1.9 million or a loss of $5 per share compared to a net loss of $4.3 million or $41.09 per share for the same period in 2021. The current period net loss includes nonrecurring other income of $2.6 million related to recognition and revaluation of the warrants issued in conjunction with our October financing.

Additionally, these loss per share amounts reflect the company’s reverse stock split that was reflected in December 2022. Prior year earnings per share have been adjusted to reflect the impact of the reverse stock split as well. At December 31, 2022, we had approximately 536,000 outstanding common shares. On January 4 of this year, our stockholders approved a proposal allowing closures of the warrants issued in the October financing to exercise those warrants. To date, 99% of the warrants have now been exercised, substantially clearing our warrant overhang. And as a result, we currently have approximately 1.2 million shares of common stock outstanding. From a liquidity perspective, we ended the fourth quarter with $18.3 million in cash, cash equivalents and marketable securities, and we have no debt on the balance sheet.

This concludes our prepared remarks. Operator, we would now like to open the call to questions.

See also 12 High Growth Software Stocks that are Profitable and 12 High Growth Healthcare Stocks to Buy.

Q&A Session

Operator: First question comes from Jeffrey Cohen, Ladenburg Thalmann. Please go ahead.

Jeffrey Cohen: Hi, Nestor, Lynn how’re you?

Nestor Jaramillo: How’re you Jeff?

Jeffrey Cohen: So a few questions from my end. Firstly, could you talk about SeaStar’s SCD for pediatric AKI? It sounds like their submission is in, and you would anticipate being able to commercialize their unit in 2023. Could you talk about time line there? And could you talk about commercialization specific to your three channels?

Nestor Jaramillo: Yes, Jeff, we’ll be glad to answer that question. SeaStar, the approval — they are applying for a humanitarian device extension. And as you know, FDA can be unpredictable, but we expect that they will receive the HDE sometime in the first half of this year. The second part of your question was about the commercialization. We’re going to do that in a stage approach. We’re going to start with our key users of the edge of the SCD device which happen to be many of them, this our top users of Aquadex into the effort. So we see a very strong strategic fit there. So we hope to be very successful once we can start commercializing the device.

Jeffrey Cohen: Okay. Got it. And Lynn, a financial question. You talked about 47% increase in cardiac in ’24 in critical care. What was the paeds number?

Lynn Blake: Paeds number was 92% for the fourth quarter year-over-year.

Jeffrey Cohen: That’s Q4 year-over-year. Okay, got it. Do you think you’ll break that out next year or this year by segment?

Lynn Blake: Well, I think we’ll continue to provide that color in our commentary. It’s not official segment reporting from a financial standpoint, but that’s how we think about our call points and our market side. So — yes.

Jeffrey Cohen: Okay. Okay. Got it. And when you talk about the unit that you’re working on, the pediatric sensing, you talk about IDE early ’24. What’s left to do between now and submitting the IDE?

Nestor Jaramillo: Well, two things. One, we need to complete the development, which is very far advanced. And then also most important is test that the performance of the device from safety and efficacy at 100%. We want to make sure that this product has the highest quality possible when we do the launch of this — we start the IDE study. The next step that we have, the immediate next step is our pre-submission to the FDA. And this is basically a formality where we inform the FDA of what our plans are, and then we have a conversation directly with them to see what is their opinion about our plans.

Jeffrey Cohen: And does the pre-sub meeting come earlier this year or latter this year?

Nestor Jaramillo: Early this year. We’re very soon to do that resubmission.

Jeffrey Cohen: Got it. And then lastly, Lynn, did you call out cash use? Q4 cash use?

Lynn Blake: I didn’t call out the Q4 number, but it was in the range of $4 million, Jeff.

Jeffrey Cohen: Got it. Okay. Perfect. Thanks for taking the questions.

Nestor Jaramillo: Yes. Thank you, Jeff.

Operator: Thank you. Next question will be from Anthony Vendetti of Maxim Group. Please go ahead.

Anthony Vendetti: Thank you. In terms of the console sales, how many were from new accounts versus existing accounts?

Nestor Jaramillo: Good question, Anthony. We had about 60% were from existing accounts and the rest was in new accounts.

Anthony Vendetti: Okay. Great. And really nice progress in the pediatric segment and good growth across the board. Can you talk about usage rates? I think you did give the — did you give the percent increase in the single-use consumable piece of that? And if not, I may have missed it. If you can just repeat it?

Nestor Jaramillo: Yes. No, we did not give a breakdown of the console versus disposables. I hear what you’re saying, Anthony, is something that we would be preparing for the future. But I think it would be a good metric for you to understand our growth, especially as we increase the placement of console, which is our razor, in our razor blade model.

Anthony Vendetti: Okay. Great. And I don’t know if Dr. Jeffries is on, but I had spoken to him during my due diligence process. If he is on, can he speak to the benefits of Aquadex and then the ability to convince his peers in the benefits of using Aquadex in terms of increasing adoption?

Nestor Jaramillo: Yes. He’s not here with us right now, Anthony. But yes, that’s one of the key roles that we have for him, is to be able to talk to his peers but as well as the medical societies that have influenced the guidelines.